2,615
Views
0
CrossRef citations to date
0
Altmetric
Research Paper

Systemic inhibition of BMP1-3 decreases progression of CCl4-induced liver fibrosis in rats

, , , , , , , , , , , , , , & show all
Pages 201-215 | Received 23 May 2017, Accepted 14 Jan 2018, Published online: 27 Feb 2018

References

  • Baghy K, Dezso K, László V, Fullár A, Péterfia B, Paku S, Nagy P, et al. 2011. Ablation of the decorin gene enhances experimental hepatic fibrosis and impairs hepatic healing in mice. Lab Invest 91:439–451.
  • Baghy K, Iozzo RV, Kovalszky I. 2012. Decorin-TGFβ axis in hepatic fibrosis and cirrhosis. J Histochem Cytochem 60:262–268.
  • Bamber J, Cosgrove D, Dietrich CF, Fromageau J, Bojunga J, Calliada F, Cantisani V, et al. 2013. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 1: Basic principles and technology. Ultraschall Med 34:169–184.
  • Bataller R, Brenner DA. 2005. Liver fibrosis. J Clin Invest 115:209–218.
  • Bi WR, Jin CX, Xu GT, Yang CQ. 2012. Bone morphogenetic protein-7 regulates Snail signaling in carbon tetrachloride-induced fibrosis in the rat liver. Exp Ther Med 4:1022–1026.
  • Bi WR, Xu GT, Lv LX, Yang CQ. 2014. The ratio of transforming growth factor-β1/bone morphogenetic protein-7 in the progression of the epithelial-mesenchymal transition contributes to rat liver fibrosis. Genet Mol Res 13:1005–1014.
  • Cai X, Li Z, Yu H, Liu K, Liang X, Wang Y, Liang Y. 2014. Isolated laparoscopic resection of the hepatic caudate lobe. Chin Med J 127:3194–3195.
  • Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G, Maimone S, et al. 2009. Computer-assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 49:1236–1244.
  • Chen BL, Peng J, Li QF, Yang M, Wang Y, Chen W. 2013. Exogenous bone morphogenetic protein-7 reduces hepatic fibrosis in Schistosoma japonicum-infected mice via transforming growth factor-β/Smad signaling. World J Gastroenterol 19:1405–1415.
  • Constandinou C, Henderson N, Iredale JP. 2005. Modeling liver fibrosis in rodents. Methods Mol Med 117:237–250.
  • Cosgrove D, Piscaglia F, Bamber J, Bojunga J, Correas JM, Gilja OH, Klauser AS, et al. 2013. EFSUMB guidelines and recommendations on the clinical use of ultrasound elastography. Part 2: Clinical applications. Ultraschall Med 34:238–253.
  • De Minicis S, Seki E, Uchinami H, et al. 2007. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 132:1937–1946.
  • Dong X, Zhao B, Iacob RE, Zhu J, Koksal AC, Lu C, Engen JR, Springer TA. 2017. Force interacts with macromolecular structure in activation of TGF-β. Nature 542:55–59.
  • Droguett R, Cabello-Verrugio C, Riquelme C, Brandan E. 2006. Extracellular proteoglycans modify TGF-beta bio-availability attenuating its signaling during skeletal muscle differentiation. Matrix Biol 25:332–341.
  • Fischer JW, Kinsella MG, Levkau B, Clowes AW, Wight TN. 2001. Retroviral overexpression of decorin differentially affects the response of arterial smooth muscle cells to growth factors. Arterioscler Thromb Vasc Biol 21:777–784.
  • Friedman SL. 2008. Mechanisms of hepatic fibrogenesis. Gastroenterology 134:1655–1669.
  • Fullár A, Firneisz G, Regős E, Dudás J, Szarvas T, Baghy K, Ramadori G, Kovalszky I. 2016. Response of hepatic stellate cells to TGFB1 differs from the response of myofibroblasts. Decorin protects against the action of growth factor. Pathol Oncol Res 23:287–294.
  • Gabr SA, Alghadir AH, Sherif YE, Ghfar AA. 2016. Biomarkers in liver disease. In: Biomarkers in Disease: Methods, Discoveries and Applications. Springer. p 1–21.
  • Ge G, Greenspan DS. 2006a. BMP1 controls TGFbeta1 activation via cleavage of latent TGFbeta-binding protein. J Cell Biol 175:111–120.
  • Ge G, Greenspan DS. 2006b. Developmental roles of the BMP1/TLD metalloproteinases. Birth Defects Res C Embryo Today 78:47–68.
  • Goodman ZD, Becker RL Jr, Pockros PJ, Afdhal NH. 2007. Progression of fibrosis in advanced chronic hepatitis C: Evaluation by morphometric image analysis. Hepatology 45:886–894.
  • Gressner OA, Gao C. 2014. Monitoring fibrogenic progression in the liver. Clin Chim Acta 433:111–122.
  • Gressner OA, Weiskirchen R, Gressner AM. 2007. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp Hepatol 6:7.
  • Grgurevic L, Christensen GL, Schulz TJ, Vukicevic S. 2016. Bone morphogenetic proteins in inflammation, glucose homeostasis and adipose tissue energy metabolism. Cytokine Growth Factor Rev 27:105–1810.
  • Grgurevic L, Macek B, Durdevic D, Vukicevic S. 2007. Detection of bone and cartilage-related proteins in plasma of patients with a bone fracture using liquid chromatography-mass spectrometry. Int Orthop 31:743–751.
  • Grgurevic L, Macek B, Healy DR, Brault AL, Erjavec I, Cipcic A, Grgurevic I, et al. 2011. Circulating bone morphogenetic protein 1-3 isoform increases renal fibrosis. J Am Soc Nephrol 22:681–692.
  • Ha T. 2017. Structural biology: Growth factor rattled out of its cage. Nature 542:40–41.
  • Hao ZM, Cai M, Lv YF, Huang YH, Li HH. 2012. Oral administration of recombinant adeno-associated virus-mediated bone morphogenetic protein-7 suppresses CCl(4)-induced hepatic fibrosis in mice. Mol Ther 20:2043–2051.
  • Hulmes DJ, Mould AP, Kessler E. 1997. The CUB domains of procollagen C-proteinase enhancer control collagen assembly solely by their effect on procollagen C-proteinase/bone morphogenetic protein-1. Matrix Biol 16:41–45.
  • Iredale JP. 2007. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest 117:539–548.
  • Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA. 1996. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2:418–423.
  • Jang JH, Kang KJ, Kim YH, Kang YN, Lee IS. 2008. Reevaluation of experimental model of hepatic fibrosis induced by hepatotoxic drugs: an easy, applicable, and reproducible model. Transplant Proc 40:2700–2703.
  • Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, et al. 2012. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. Proc Natl Acad Sci U S A 109:9448–9453.
  • Li L, Okada H, Takemura G, Kosai K, Kanamori H, Esaki M, Takahashi T, et al. 2009. Postinfarction gene therapy with adenoviral vector expressing decorin mitigates cardiac remodeling and dysfunction. Am J Physiol Heart Circ Physiol 297:H1504–H1513.
  • Liu X, Hu H, Yin JQ. 2006. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 26:8–22.
  • Liu Y, Yang J. 2006. Hepatocyte growth factor: New arsenal in the fights against renal fibrosis? Kidney Int 70:238–240.
  • Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408.
  • Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63.
  • Nanji AA, Mendenhall CL, French SW. 1989. Beef fat prevents alcoholic liver disease in the rat. Alcohol Clin Exp Res 13:15–19.
  • Pauk M, Grgurevic L, Brkljacic J, Kufner V, Bordukalo-Niksic T, Grabusic K, Razdorov G, et al. 2015. Exogenous BMP7 corrects plasma iron overload and bone loss in Bmp6-/- mice. Int Orthop 39:161–172.
  • Rockey DC, Bell PD, Hill JA. 2015. Fibrosis-a common pathway to organ injury and failure. N Engl J Med 373:96.
  • Rockey DC. 2008. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis 12:939–962.
  • Smits K, Goossens K, Van Soom A, Govaere J, Hoogewijs M, Vanhaesebrouck E, et al. 2009. Selection of reference genes for quantitative real-time PCR in equine in vivo and fresh and frozen-thawed in vitro blastocysts. BMC Res Notes 2:246.
  • Sristastava AK, Khare P, Nagar HM, Raghuwanshi N, Srivastava R. 2016. Hydroxyproline: A potential biochemical marker and its role in the pathogenesis of different diseases. Curr Protein Pept Sci 17:596–602.
  • Sugimoto H, Yang C, LeBleu VS, Soubasakos MA, Giraldo M, Zeisberg M, Kalluri R. 2007. BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J 21:256–264.
  • Tacke F, Gäbele E, Bataille F, Schwabe RF, Hellerbrand C, Klebl F, Straub RH, et al. 2007. Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci 52:3404–3415.
  • Takahara K, Lyons GE, Greenspan DS. 1994. Bone morphogenetic protein-1 and a mammalian tolloid homologue (mTld) are encoded by alternatively spliced transcripts which are differentially expressed in some tissues. J Biol Chem 269:32572–32578.
  • von Marschall Z, Fisher LW. 2010. Decorin is processed by three isoforms of bone morphogenetic protein-1 (BMP1). Biochem Biophys Res Commun 391:1374–1378.
  • Vukicevic S, Grgurevic L. 2016. Bone morphogenetic proteins in inflammation. In: Parnham MJ, Editor. Compendium of Inflammatory Diseases. Basel: Springer International Publishing AG. p 229–242.
  • Wang LP, Dong JZ, Xiong LJ, Shi KQ, Zou ZL, Zhang SN, Cao ST. 2014. BMP-7 attenuates liver fibrosis via regulation of epidermal growth factor receptor. Int J Clin Exp Pathol 7:3537–3547.
  • Wang SL, Yang CQ, Qi XL, et al. 2013. Inhibitory effect of bone morphogenetic protein-7 on hepatic fibrosis in rats. Int J Clin Exp Pathol 6:897–903.
  • Wynn TA. 2008. Cellular and molecular mechanisms of fibrosis. J Pathol 214:199–210.
  • Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, Blaner WS, Mukherjee P, et al. 2005. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54:142–151.
  • Yamaguchi Y, Mann DM, Ruoslahti E. 1990. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346:281–284.
  • Yan W, Wang P, Zhao CX, Tang J, Xiao X, Wang DW. 2009. Decorin gene delivery inhibits cardiac fibrosis in spontaneously hypertensive rats by modulation of transforming growth factor-beta/Smad and p38 mitogen-activated protein kinase signaling pathways. Hum Gene Ther 20:1190–1200.
  • Yang T, Chen SL, Lu XJ, Chen YP. 2012. Bone morphogenetic protein 7 suppresses the progression of hepatic fibrosis and regulates the expression of gremlin and transforming growth factor β1. Mol Med Rep 6:246–252.
  • Zeisberg M, Yang C, Martino M, Duncan MB, Rieder F, Tanjore H, Kalluri R. 2007. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282:23337–23347.
  • Zhong L, Wang X, Wang S, Yang L, Gao H, Yang C. 2013. The anti-fibrotic effect of bone morphogenic protein-7(BMP-7) on liver fibrosis. Int J Med Sci 10:441–450.